Vertex Pharmaceuticals upgraded to "outperform"
02/01/10 - Oppenheimer
NEW YORK, February 1 (newratings.com) - Analysts at Oppenheimer & Co upgrade Vertex Pharmaceuticals Incorporated (VRTX) from "perform" to "outperform." The target price is set to $47.
Share Recommend this article to a friend add VRTX to my stocks and get e-mail alerts on Vertex Pharmaceuticals